Connect the right patient to the right treatment, resources, and community.

Amantadine is also an older medication that was initially developed to help prevent influenza Type A. It was subsequently found to have a mild but definite effect on Parkinson’s without worsening typical symptoms. More recently, it has been found to be helpful in reducing levodopa-induced dyskinesias and now is predominantly used in advanced Parkinson’s disease for this purpose. Furthermore, the use of amantadine followed by a dopamine agonist tends to lower the incidence of Levodopa-induced Dyskinesia (LID) compared to a dopamine agonist alone.

There are both on-label extended-release and off-label immediate-release options for amantadine. Adverse effects with amantadine are not uncommon and include swelling of the feet, dry mouth, constipation, vivid dreams, dizziness, and hallucinations.  There is a once-daily extended-release, high-dose preparation given at bedtime that is specifically indicated for dyskinesias as well as OFF episodes. There is also an off-label variety of amantadine given twice daily but is not specifically FDA-approved for dyskinesia.

Discuss your options regarding the use of amantadine and its side effects with your doctor before implementing any new therapies into your routine.